-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Due to doubts about the profit distribution plan, on April 28, the Shenzhen Stock Exchange issued a letter of concern to Jiangsu Hualv Biological Technology Co.
, Ltd.
(hereinafter referred to as "Hualv Biological"), requesting it to say whether there is any speculation in its profit distribution plan.
The cash dividend distribution of controlling shareholders and their affiliates
.
On April 28, Hualv Biological disclosed the "Announcement on the 2020 Profit Distribution and High-Government Plan".
Based on the company’s current total share capital of 58.
35 million shares, it will distribute a cash dividend of RMB 5.
2 for every 10 shares, and a total cash dividend will be distributed.
The dividend was 30.
342 million yuan; the capital reserve was used to transfer 10 shares for every 10 shares to all shareholders, for a total of 58.
35 million shares
.
The Shenzhen Stock Exchange requested Hualv Biological to explain the basis and rationality of the profit distribution plan, whether it matches the company's performance growth, and whether there is any speculation in the stock price
In addition, Hualv Biotech’s controlling shareholder and actual controller Yu Yangchao and his spouse collectively hold 39.
14% of the company’s shares.
The equity concentration is relatively high.
The Shenzhen Stock Exchange requires the company to explain whether there is cash dividend distribution to the controlling shareholder and its affiliates that damages the listing.
The situation of the company's interests
.
According to data, Hualv Bio was established in 2010 and is mainly engaged in the research and development, planting and sales of edible fungi.
Its main products are enoki mushrooms, real mushrooms (including crab-flavored mushrooms and white jade mushrooms)
.
On the same day, Hualv Biological released its 2020 annual report, stating that it achieved operating income of 609 million yuan last year, an increase of 5.
